Table 2 Relationship between PSMC2 expression and tumor characteristics in patients with gastric cancer.
From: PSMC2 promotes the progression of gastric cancer via induction of RPS15A/mTOR pathway
Features | No. of patients | PSMC2 expression | P value | |
|---|---|---|---|---|
Low | High | |||
All patients | 93 | 57 | 36 | |
Age (years) | 0.016* | |||
≤65 | 47 | 35 | 12 | |
>65 | 44 | 22 | 22 | |
Gender | 0.244 | |||
Male | 61 | 40 | 21 | |
Female | 32 | 17 | 15 | |
Grade | 0.715 | |||
2 | 13 | 7 | 6 | |
3 | 70 | 44 | 26 | |
4 | 10 | 6 | 4 | |
Tumor Infiltrate | 0.003** | |||
T1 | 7 | 7 | 0 | |
T2 | 7 | 5 | 2 | |
T3 | 59 | 37 | 22 | |
T4 | 19 | 7 | 12 | |
Lymphatic metastasis (N) | 0.088 | |||
N0 | 24 | 18 | 6 | |
N1 | 13 | 8 | 5 | |
N2 | 25 | 14 | 11 | |
N3 | 29 | 15 | 14 | |
Tumor metastasis | 0.512 | |||
No | 84 | 52 | 32 | |
Yes | 8 | 4 | 4 | |
Stage | 0.011* | |||
1 | 9 | 7 | 2 | |
2 | 28 | 22 | 6 | |
3 | 47 | 22 | 25 | |
4 | 7 | 4 | 3 | |
Tumor size | 0.156 | |||
<6 cm | 45 | 31 | 14 | |
≥6 cm | 46 | 25 | 21 | |
Lymph node positive | 0.077 | |||
≤4 | 46 | 32 | 14 | |
>4 | 43 | 22 | 21 | |
Expression of Ki67 | 0.015* | |||
Low | 51 | 37 | 14 | |
High | 42 | 20 | 22 | |